What a split-sample exercise can establish, and what it cannot
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
July 2024
Everything filed in July 2024, the month of Volume 1, Number 7. The issue itself — cover, editor’s letter and table of contents — is here.
Ireland health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
From the floor in Hong Kong: 20 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The 27-day notice: how a compounding wind-down works in Denmark
The document is four pages. Three of them are about dates.
Lipohypertrophy, and the absorption it ruins
A rotation scheme that is too complicated will not be followed. We describe the simple ones that are.
The interventions with trial support, and the much longer list without
The intervention with the clearest evidence is the one nobody frames as an intervention: adjusting the dose.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A supplier suspends shipping to Mexico after 3 consecutive customs detentions
The route did not close because of a rule about peptides.
SURMOUNT-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
How a claim degrades between the bench and the listing
Every step between the laboratory report and the product page removes information, and the badge is the last step.
Collapse temperature, and the hour of the cycle where shelf life is lost
Lyophilisation does not stop degradation. It slows every pathway by removing the solvent that most of them require, and the residue of solvent that remains sets the rate.
A shortage listing ends. 10 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
From the floor in Shenzhen: 16 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
What a 36% rise in coupling-reagent prices does to a 30 mg vial
Follow the resin, not the catalogue.
What a 1 mL syringe does that a 0.3 mL syringe does not
The graduation interval differs between barrel sizes, and a 1 mL barrel is frequently marked in two-unit steps. Reading one as though it were marked in single units halves…
How a claim degrades between the bench and the listing
What a verification mark would have to carry to be checkable: a date, a lot, a method, a submitter and a link to the report.
What changed at FGP in July, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
PeptideMeter result on a Suzhou retatrutide lot lands 2.2 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
The supply gap as a clinical event
Why the reason for stopping changes what happens afterwards.
Which results are findings and which are consequences of the weight loss
Three different explanations for the same abnormal number, and how to tell them apart.
Twenty-eight days is a number from somebody else’s product
We set out what is known, what is inferred and what is simply assumed about the fortnight after a vial is opened.
Shenzhen export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
New Zealand declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The online reseller trading as Adamant Research Supply closes after 5 years
A proper account of an operation that existed, and of what closing it cost.
The 11-day notice: how a compounding wind-down works in Switzerland
The document is four pages. Three of them are about dates.
Retest date, expiry date, and the two conventions being confused
What happens to traceability when bulk material is subdivided, repackaged and relabelled two or three times before sale.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What a 37% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A supplier suspends shipping to Switzerland after 22 consecutive customs detentions
The route did not close because of a rule about peptides.
The incretin receptors, ranked by how much we actually know about them
The receptor is expressed in more tissues than the popular account allows, and that is the whole story.
Discontinuation rates, read honestly
An effect is dose-limiting when it prevents adequate intake, prevents normal activity, or produces a risk of its own. Discomfort alone is not the test.
Xianning export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Ireland pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
A named analyst is the cheapest quality signal in this trade
What the Journal asks when a document arrives unsigned, and what the answers have been.
Two sessions a week, and the evidence behind the prescription
The recommendation survives scrutiny. The reasoning offered for it frequently does not.